Welcome to our dedicated page for Lifecore Biomedical SEC filings (Ticker: LFCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for a sterile injectable CDMO like Lifecore Biomedical (LFCR) can feel like navigating a lab notebook—dense with GMP jargon, hyaluronic acid production stats and quality-system validations. If you've ever searched for “Lifecore Biomedical SEC filings explained simply,” you know the challenge of extracting CDMO revenue trends or spotting fermentation capacity disclosures buried deep in a 300-page report.
Stock Titan solves that problem. Our AI identifies what matters in every document, from the Lifecore Biomedical annual report 10-K simplified to each Lifecore Biomedical quarterly earnings report 10-Q filing. Instantly surface segment margins, backlog changes and risk-factor shifts. Need real-time alerts? We stream Lifecore Biomedical Form 4 insider transactions real-time, flagging executive stock sales the moment they hit EDGAR. For sudden contract wins or FDA updates, the platform breaks down Lifecore Biomedical 8-K material events explained so you grasp the impact without parsing legalese.
- Track Lifecore Biomedical insider trading Form 4 transactions alongside price charts.
- Compare fermentation vs. fill-finish performance with our Lifecore Biomedical earnings report filing analysis.
- Review board pay in the latest Lifecore Biomedical proxy statement executive compensation.
- Save hours by understanding Lifecore Biomedical SEC documents with AI summaries.
- Monitor Lifecore Biomedical executive stock transactions Form 4 before key announcements.
Every filing type—10-K, 10-Q, 8-K, Form 4—lands here seconds after EDGAR posts, complete with plain-English context and expert commentary. Whether you’re modeling capacity expansion or checking compliance milestones, our AI-powered analysis turns Lifecore’s complex disclosures into actionable insight.
Key take-away: Leidos Holdings, Inc. (LDOS) has filed a Form 4 indicating routine director compensation in stock.
On 10 July 2025, the company reported that director Harry M. Jansen Kraemer Jr. acquired 200.5059 shares of Leidos common stock on 8 July 2025. The shares were credited at a price of $0.00 because the director elected to defer his quarterly board retainer into the company’s Key Executive Stock Deferral Plan. After the transaction, Mr. Kraemer’s indirect holdings in the plan total 127,890.1673 shares. No open-market purchases, dispositions, or derivative security activities were reported.
The filing reflects standard board compensation practice and does not materially affect Leidos’ share count or insider ownership profile.
Lifecore Biomedical (LFCR) – CFO insider equity transaction
On 07/08/2025, Chief Financial Officer Ryan D. Lake reported the vesting of 75,000 performance-based restricted stock units (RSUs). The units converted into common shares (Form 4, code M), lifting his direct holdings to 392,429 shares.
To satisfy statutory tax withholding, the issuer automatically withheld 32,806 shares at $8.19 per share (code F). After this offset, Lake’s direct ownership stands at 359,623 shares, a net increase of roughly 42 k shares versus the pre-transaction level. He also retains 600,000 unexercised performance-based RSUs that continue to vest through 09/03/2029 once additional share-price milestones are achieved.
The filing reflects routine equity-compensation settlement rather than an open-market purchase or discretionary sale. Nonetheless, the additional shares keep the CFO’s incentives aligned with shareholder value creation.
Smith-Midland Corporation (NASDAQ: SMID) delivered a markedly stronger first quarter of 2025, leveraging a large, high-margin barrier-rental project to lift both revenue and profitability. All figures are unaudited and expressed in thousands, except per-share data.
- Revenue jumped 35% year-over-year to $22.7 million (Q1-24: $16.8 million). The key driver was barrier rentals, which rose eight-fold to $8.4 million, offsetting a 15% slide in product sales.
- Gross profit nearly doubled to $7.0 million, expanding gross margin to 30.7% (Q1-24: 23.3%) as rental mix improved cost leverage (cost of sales fell to 72% of sales from 79%).
- Operating income advanced 191% to $4.4 million; net income climbed 190% to $3.3 million, driving basic EPS to $0.63 versus $0.22 a year ago.
- Cash increased to $9.0 million (12/31/24: $7.5 million) after generating $2.2 million of operating cash flow; long-term debt declined slightly to $4.3 million and the $5.0 million revolver remains undrawn.
- Balance sheet strength: Equity rose to $45.1 million, representing 60% of total assets. Tangible-net-worth and capital-spending covenants under bank facilities remain in compliance.
- Backlog at 5 May 2025 was $52.4 million, down 19% from $64.6 million a year earlier; management expects most projects to convert to revenue within 12 months.
- Management reiterated its strategy to expand SlenderWall sales, grow barrier-rental fleet and pursue infrastructure-linked demand; planned 2025 capex totals ~$5 million.
Operational considerations
- One customer accounted for 33% of Q1-25 revenue; two customers each represented >10% of receivables.
- A ransomware incident occurred in Q1-25 but was resolved without payment; network security changes were implemented.
- Material weaknesses in entity-level and IT controls identified in 2024 remain unremediated; a new CFO was hired and remediation efforts are under way.
Outlook: Management anticipates sustained soundwall and building demand, incremental SlenderWall orders in 2H-25 and continued emphasis on barrier rentals. However, reduced backlog, customer concentration and unresolved control weaknesses introduce execution and governance risk.
FAQ
What is the current stock price of Lifecore Biomedical (LFCR)?
What is the market cap of Lifecore Biomedical (LFCR)?
What is Lifecore Biomedical Inc.'s primary business?
What are the main segments of the company's operations?
How does Lifecore ensure product quality?
Who are Lifecore's typical clients?
What distinguishes Lifecore in the competitive biopharma market?
What kinds of products does Lifecore manufacture?
How long has Lifecore been active in this industry?
What regulatory standards does Lifecore adhere to?
